Numerous GLP-1 RA and SGLT2i presentations touted their clinical results, providing continued excitement for our BETonMACE program, which observed a non-prespecified 63% reduction in MACE and heart failure hazard among patients taking next-generation glucose lowering drugs Calgary, Alberta--(Newsfile Corp. - September 3, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or "the Company") today announced its presentation at... Read More

Calgary, Alberta--(Newsfile Corp. - July 31, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual & Special Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected four (4) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as... Read More

Calgary, Alberta--(Newsfile Corp. - July 16, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced it has entered into definitive transaction documents for the two-year extension of the Company's US$6.0 million secured convertible debenture (the "Debenture") with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to... Read More

Calgary, Alberta--(Newsfile Corp. - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024. A Notice of Meeting and Management Information Circular, containing the matters to be... Read More

Calgary, Alberta--(Newsfile Corp. - May 13, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today a two-year extension of the Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink") (and payment of accrued interest thereon), extending the maturity date to May 13, 2026. In connection with the extension, Hepalink's conversion... Read More

Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's President and CEO. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage... Read More

Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, " The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation, " by Dr. Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40 th peer-reviewed... Read More

Calgary, Alberta--(Newsfile Corp. - October 4, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of a peer-reviewed article, entitled " Apabetalone, a Clinical-stage, Selective BET Inhibitor, Opposes DUX4 Target Gene Expression in Primary Human FSHD Muscle Cells " in the journal Biomedicines. "The beneficial effect of apabetalone highlighted in these models of facioscapulohumeral muscular... Read More

Amsterdam, Netherlands and Calgary, Alberta--(Newsfile Corp. - August 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") (TSX:RVX) today announced that new guidelines published by the European Society of Cardiology (ESC) reflect unmet need in the reduction of cardiovascular risk in patients with type 2 diabetes, and highlight the opportunity for apabetalone to benefit this high-risk population. New emphasis on... Read More

Calgary, Alberta--(Newsfile Corp. - June 29, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announces that certain of its 27,461,157 common share purchase warrants (the "Warrants") will be amended. Commencing on July 17, 2023, the exercise price of 24,508,489 Warrants (currently exercisable at prices ranging from $0.24 to $1.00 per share) will be reduced to $0.20 per share, and the expiry date of... Read More

Calgary, Alberta--(Newsfile Corp. - June 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", or the "Corporation") today held its Annual Meeting of Shareholders (the "Meeting") in Calgary, Alberta. During business proceedings at the Meeting, shareholders elected five (5) Board members until the next annual meeting. The voting results of shares represented at the Meeting for individual directors were as follows: Votes... Read More

Calgary, Alberta--(Newsfile Corp. - June 12, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced a peer-reviewed article, entitled, " Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment, " by Dr. Dean Gilham and colleagues, was published in Biomedicines, a prestigious scientific journal. The article explores the favorable impact... Read More

Calgary, Alberta--(Newsfile Corp. - March 20, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that it has closed a one-year extension of Company's US$6.0 million secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group Co., Ltd. ("Hepalink"), and payment of accrued interest thereon, extending the maturity date to May 13, 2024. In connection with the extension, the... Read More

Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled " Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation " by Fu et al., was published in International... Read More